It’s important to emphasize that this is not an opioid crisis, it’s a prescription opioid crisis, said Sean C. Dowdy, MD, chair, division of gynecologic surgery, department of obstetrics and gynecology, Mayo Clinic.
It’s important to emphasize that this is not an opioid crisis, it’s a prescription opioid crisis, said Sean C. Dowdy, MD, chair, division of gynecologic surgery, department of obstetrics and gynecology, Mayo Clinic.
Transcript
What interventions have been put in place to reduce opioid abuse in patients undergoing surgery for gynecologic malignancies?
The first part is just awareness. I think it’s important to emphasize that this is not an opioid crisis, it’s a prescription opioid crisis. For instance, Prince and Tom Petty, they didn’t die of heroin overdoses, they died of prescription fentanyl overdoses. So, while I think the pharmaceutical companies bare some responsibility, the fact is that patients get their prescriptions from physicians, so we really need to take charge of this and have a response to how to deal with this.
So, the first past is awareness. The second apart is, again, just making a change to our practice. We need to inject incisions so patients have better pain control, we need to optimize nonopioid alternatives, like ibuprofen and Tylenol, and patients need to be educated about this, as well. We shouldn’t just give every patient a prescription for oxycodone when they leave the hospital. They should only get it if they need it, and if they get these prescriptions, they should be in relatively small amounts.
For example, for patients with ovarian cancer surgery, this is a big laparotomy from pubic synthesis to xiphoid process, our guidelines are that the patients only get 10 pills when they leave the hospital. We have not seen an increase in refills, and patients still have good pain scores. So, really, we’ve been overprescribing pretty significantly before that change.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More